Last reviewed · How we verify
MAXOMAT ®, biosynthetic growth hormone
MAXOMAT is a biosynthetic human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and protein synthesis.
MAXOMAT is a biosynthetic human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and protein synthesis. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults.
At a glance
| Generic name | MAXOMAT ®, biosynthetic growth hormone |
|---|---|
| Sponsor | Sanofi |
| Drug class | Growth hormone (recombinant human growth hormone) |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
As a recombinant growth hormone, MAXOMAT mimics endogenous human growth hormone by activating GH receptors on target tissues, promoting linear growth in children with growth hormone deficiency, enhancing protein synthesis, and modulating metabolic processes including lipolysis and glucose homeostasis.
Approved indications
- Growth hormone deficiency in children
- Growth hormone deficiency in adults
Common side effects
- Injection site reactions
- Headache
- Hyperglycemia
- Fluid retention
- Carpal tunnel syndrome
- Arthralgia
Key clinical trials
- A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is (PHASE3)
- Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome (PHASE3)
- MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAXOMAT ®, biosynthetic growth hormone CI brief — competitive landscape report
- MAXOMAT ®, biosynthetic growth hormone updates RSS · CI watch RSS
- Sanofi portfolio CI